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Does urinary neutrophil
gelatinase-associated lipocalin
really solve the issue of
discriminating prerenal from
intrinsic acute kidney injury?
To the Editor: Singer et al.1 reported on the diagnostic value
of urinary neutrophil gelatinase-associated lipocalin (uNGAL)
in the discrimination of intrinsic and prerenal acute kidney
injury (AKI), concluding that uNGAL signiﬁcantly improves
diagnostic capacity. For several reasons, we feel that this
conclusion might be overoptimistic.
First, a biomarker would be most valuable when there is
doubt about the correct diagnosis of intrinsic vs. prerenal
AKI. Currently, this differential diagnosis is made on the
basis of patient history, volume status, the use of nephrotoxic
medications, and so on; using this approach as the gold
standard, no clear differential diagnosis could be made in a
substantial number of cases (38 out of 145); however, in this
group, uNGAL was not able to make a discrimination as well.
Thus, uNGAL is not helping in the discrimination in those
patients in whom it would be most needed. Second, the
diagnostic accuracy of the multivariate model increases only
modestly from 68.3 to 74.5 % when uNGAL is added. It
would have been interesting to see the effect of inclusion
of other parameters, such as urinary volume or evolution of
serum creatinine in the ﬁrst 4 h of admission.
Third, the authors use a composite end point, including
factors with a substantially different impact: mortality was put
at the same level as renal replacement therapy and step-up of
RIFLE class.
Fourth, authors use RIFLE rather than the Acute Kidney
Injury Network classiﬁcation.2 In contrast to the former,
the latter requires that patients be volume-repleted. If
the authors1 would have applied this strategy, they would
probably already have distinguished the majority of the
prerenal cases, as is obvious from Figure 2, in which it can
clearly be seen that serum creatinine is decreasing in the
prerenal subjects. Furthermore, the additional discriminatory
value of uNGAL would be less than that presented in the
current analysis.
In conclusion, we believe that the paper by Singer et al1
does not change the message that the diagnostic value of
uNGAL is overoptimistic.3 Advocating the use of uNGAL
might lead to neglecting other important clinical criteria.
1. Singer E, Elger A, Elitok S et al. Urinary neutrophil gelatinase-associated
lipocalin distinguishes pre-renal from intrinsic renal failure and predicts
outcomes. Kidney Int 2011; 80: 405–414.
2. Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report of
an initiative to improve outcomes in acute kidney injury. Crit Care 2007;
11: R31.
3. Lameire N, Vanholder R, Van Biesen W. How to use biomarkers efficiently
in acute kidney injury. Kidney Int 2011; 79: 1047–1050.
Wim Van Biesen1, Jill Van Massenhove1,
Norbert Lameire1 and Raymond Vanholder1
1Renal Division, University Hospital Ghent, Ghent, Belgium
Correspondence: Wim Van Biesen, Renal Division, University
Hospital Ghent, Ghent 9000, Belgium. E-mail: wim.vanbiesen@ugent.be
Kidney International (2012) 81, 321; doi:10.1038/ki.2011.382
The Authors Reply: We thank Drs Van Biesen et al.1 for
their letter regarding our study where they question the
diagnostic utility of determining urinary neutrophil gelati-
nase-associated lipocalin (uNGAL) in patients that present
with elevated serum creatinine. Among physicians, nephrol-
ogists are particularly aware that the disease phenotype is
critically time-dependent as patients can be, e.g., in positive
sodium balance without edema, or in complete renal failure
with ‘normal’ serum creatinine. In addition, decreases in
glomerular ﬁltration rate are part of the normal homeostatic
response to marked reductions of extracellular ﬂuid volume
and also to the neurohumoral response triggered by diseases
in which cardiovascular homeostasis is compromised, i.e.,
congestive heart failure, hypoalbuminemia, and so on. In all
these conditions, serum creatinine can be elevated and
whether this is due to an appropriate renal response to
neurohumoral signals (i.e., prerenal) or to an intrinsic acute
kidney injury (AKI) has vexed physicians and nephrologists
for decades. Indeed, true distinctions of ‘prerenal’ vs.
‘intrinsic renal’ increases in plasma creatinine are only
made retrospectively depending on the patient’s response
to therapy. Moreover, in rich societies ‘prerenal’ increases
in plasma creatinine are most often due to abnormal
cardiovascular function so that acute administration of
volume is often not indicated. Given these complexities,
development of a test that immediately assists the physician
confronting a patient with an elevated serum creatinine would
be highly valuable. Our study now adds to a growing body of
evidence supporting the concept that NGAL correlates with
processes that induce intrinsic AKI, but not with transient
pre-renal elevations of creatinine.2–4
Speciﬁcally, Van Biesen et al.1 suggested that a volume-
repleted study population should have been selected, but this
would have obscured our intention to test the prospective
discriminatory ability of uNGAL. Furthermore, we would
imagine that 4-h repeat measurements of urinary output and
serum creatinine would be neither sensitive nor compatible
with rapid triage. Moreover, similar to previous studies,4,5
NGAL predicted poor clinical outcomes whether mortality was
included into a composite outcome (our paper) or only renal-
speciﬁc outcomes were considered (Table 1). Van Biesen et al.1
are particularly concerned with the utility of uNGAL in
patients who were unclassiﬁable. We point out that we aimed
to make gold standard diagnoses of prerenal and intrinsic AKI,
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